APVO news

Aptevo successfully refined mipletamig's priming dose to reduce patient infusion reactions. This improves tolerability for frontline AML patients, strengthening the drug's profile for Phase 2 development.

Aptevo Therapeutics filed an exhibit 5.1 legal opinion in relation to a sales agreement authorizing the sale of up to $2.3M in common stock, by Roth Capital Partners.

Ten patients advanced to transplant after treatment with mipletamig, a 30-fold increase over historical VEN+AZA rates, supporting further clinical development.

Aptevo Therapeutics will present at the Society for Immunotherapy of Cancer to highlight its CD40-directed multispecific portfolio and platform technology designed to coordinate innate and adaptive immunity. This business update highlights the ce company's pipeline progress and remains relevant for …

Aptevo Therapeutics reported a 93% clinical benefit rate in evaluable TP53-mutated AML patients treated with its mipletamig triplet, nearly double published venetoclax outcomes, showcasing potential for a difficult-to-treat population.

Aptevo Therapeutics filed a patent application covering a versatile Nectin-4 x PD-L1 backbone intended to support multiple solid tumor therapies and unlock value for partners.

Aptevo Therapeutics and Niowave announced a strategic partnership to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment representing 7.9% ownership and potential to reach 19.99% through warrants. The collaboration combines Aptevo's multi…